President Trump announced agreements with pharmaceutical firms Eli Lilly and Novo Nordisk to reduce the prices of GLP-1 drugs when purchased through Medicare, Medicaid and the TrumpRx platform.[1][4] Ozempic and Wego's drug prices will drop from $1,000 and $1,350 per month to $350 via TrumpRx.[4] Zepbound and Orforglipron (if approved) will cost an average of $346 per month instead of $1,086.[4] An initial dose of oral GLP-1 drugs like Wego's in tablet form will cost $150 a month through TrumpRx.[4] Starting in April 2026, Medicare will cover GLP-1 drugs for patients with obesity and related diseases through special demonstration projects.[3] TrumpRx is a direct-to-consumer program that will begin operating in early 2026 and will allow purchases at lower prices without middlemen.[1][7] These changes are intended to reduce the cost of drugs for diabetes, obesity and heart disease.[4]